Ignite Creation Date:
2024-05-06 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05167643
Status:
UNKNOWN
Last Update Posted:
2022-04-07
First Post:
2021-11-03
Brief Title:
H Trastuzumab or Biosimilar Combined With CDK46 Inhibitor AIOFS in the Treatment of HRHER2 Advanced Breast Cancer Efficacy and Safety a Chinese Multi-center Real World Study
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Organization Data
Organization:
Tianjin Medical University Cancer Institute and Hospital
Class:
OTHER
Study ID:
BC-CIH-H-RWS
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None